2024-11-20 - Analysis Report
## Abbott Laboratories (ABT) Stock Analysis Report

**1. Performance Relative to S&P 500 (VOO):**

Abbott Laboratories (ABT) is a global healthcare company that develops, manufactures, and sells a broad range of health care products.  The cumulative return of ABT is 96.37%, while the S&P 500 (VOO) shows a cumulative return of 124.78%.  This represents a difference of -28.41%.  Considering the historical range of the relative divergence (max: 78.22%, min: -45.09%), ABT's current performance is at the 13.53% percentile relative to the S&P 500.  Therefore, ABT has underperformed the S&P 500 over the measured period.

The provided Alpha and Beta analysis shows a generally consistent Beta around 1.1, indicating the stock's volatility is slightly higher than the market's. Alpha varies, indicating periods of outperformance and underperformance relative to the market benchmark. The CAGR (Compound Annual Growth Rate) shows significant variation from year to year.  The Maximum Drawdown (MDD) suggests periods of substantial losses.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 36.2% | 18.4% | -2.2% | 1.1 | 99.0 |
| 2016-2018  | 80.0% | 13.9% | 47.7% | 1.1 | 125.5 |
| 2017-2019  | 135.6% | 11.7% | 83.9% | 1.1 | 150.7 |
| 2018-2020  | 95.8% | 30.5% | 48.5% | 0.9 | 189.9 |
| 2019-2021  | 112.3% | 30.5% | 12.3% | 0.8 | 244.1 |
| 2020-2022  | 32.4% | 30.5% | 8.8% | 0.8 | 190.4 |
| 2021-2023  | 6.2% | 28.2% | -28.7% | 0.7 | 190.9 |
| 2022-2024  | -10.7% | 27.3% | -39.1% | 0.7 | 201.0 |


**2. Recent Price Movement:**

* Closing Price: 117.36 (Last Market: 116.92)
* 5-Day Moving Average: 116.09
* 20-Day Moving Average: 115.96
* 60-Day Moving Average: 114.93

The price is slightly above the short-term moving averages, suggesting a relatively stable trend.

**3. Technical Indicators & Expected Return:**

* RSI: 62.06 (Neither overbought nor oversold)
* PPO: -0.06 (Slightly bearish)
* 20-Day Relative Divergence Change: -0.75 (Short-term downward trend)
* Expected Return (2+ years): 0.0% (This indicates no expected outperformance relative to the S&P 500 over the long term based on the provided data.  This needs further investigation.)

The price of 116.92 does not show signs of a sharp increase or decrease.

**4. Recent Financial Performance:**

The provided earnings data shows relatively stable revenue but EPS fluctuates.  More context is needed to assess the performance against expectations.  It's crucial to compare these figures to analyst estimates for a complete picture.

| Date       | EPS  | Revenue     |
|------------|------|-------------|
| 2024-10-31 | 0.94 | $10.63 B    |
| 2024-07-31 | 0.74 | $10.38 B    |
| 2024-05-02 | 0.7  | $9.96 B     |
| 2023-11-01 | 0.82 | $10.14 B    |
| 2024-10-31 | 0.82 | $10.14 B    | *(Duplicate entry - please clarify)*


**6. Financial Information Analysis:**

The revenue and profitability data show consistent revenue and a stable profit margin hovering around 55%.  ROE (Return on Equity) fluctuates, suggesting variability in the efficiency of using shareholder equity to generate profits.  Further analysis is needed to understand the underlying reasons for these fluctuations.

**7. News and Recent Issues:**

*(This section requires information from recent news sources like Shacknews and Finbold within the last two days.  Please provide the relevant news articles for a proper analysis.)*  This analysis requires real-time data that I, as an AI, cannot access.  To complete this section, please supply the recent news articles.  The analysis would then cover:  Recent Market Outlook, Analyst Opinions and Performance Highlights.


**8. Overall Summary:**

Abbott Laboratories (ABT) has demonstrated relatively stable revenue and profit margins over the past quarters.  However, it has underperformed the S&P 500 in the given timeframe.  Technical indicators suggest a neutral to slightly bearish sentiment.  The long-term outlook requires a closer look at the latest earnings reports and analyst estimates, along with relevant news and market conditions. The lack of analyst opinions and recent news prevents a complete picture. A thorough analysis of the latest earnings announcement, including a comparison to analyst estimates, is essential.

**9. Disclaimer:** This report is for informational purposes only and does not constitute financial advice.  Investing in the stock market involves risk, and past performance is not indicative of future results.  Consult with a qualified financial advisor before making any investment decisions.
